2023
Pericytes are protective in experimental pneumococcal meningitis through regulating leukocyte infiltration and blood–brain barrier function
Teske N, Dyckhoff-Shen S, Beckenbauer P, Bewersdorf J, Engelen-Lee J, Hammerschmidt S, Kälin R, Pfister H, Brouwer M, Klein M, Glass R, van de Beek D, Koedel U. Pericytes are protective in experimental pneumococcal meningitis through regulating leukocyte infiltration and blood–brain barrier function. Journal Of Neuroinflammation 2023, 20: 267. PMID: 37978545, PMCID: PMC10655320, DOI: 10.1186/s12974-023-02938-z.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlood-Brain BarrierChemokinesCytokinesHumansLeukocytesMeningitis, PneumococcalMicePericytesStreptococcus pneumoniaeZebrafishConceptsModel of pneumococcal meningitisPneumococcal meningitisLeukocyte infiltrationAnimal model of pneumococcal meningitisPrevented blood-brain barrierToll-like receptor inhibitorsDegree of leukocyte infiltrationSerotypes of Streptococcus pneumoniaeUnfavorable disease courseBlood-brain barrier disruptionHuman pericytesExperimental pneumococcal meningitisBlood-brain barrier integrityRegulating leukocyte infiltrationBlood-brain barrier functionRegulation of cerebral blood flowAdult mouse modelInfection in vivoUpregulation of chemokine expressionIncreased cerebral edemaMaintenance of blood-brain barrier integrityBlood-brain barrierCerebral blood flowMouse meningitis modelIn vitro studies
2018
Mast Cells Are Activated by Streptococcus pneumoniae In Vitro but Dispensable for the Host Defense Against Pneumococcal Central Nervous System Infection In Vivo
Fritscher J, Amberger D, Dyckhoff S, Bewersdorf J, Masouris I, Voelk S, Hammerschmidt S, Schmetzer H, Klein M, Pfister H, Koedel U. Mast Cells Are Activated by Streptococcus pneumoniae In Vitro but Dispensable for the Host Defense Against Pneumococcal Central Nervous System Infection In Vivo. Frontiers In Immunology 2018, 9: 550. PMID: 29616039, PMCID: PMC5867309, DOI: 10.3389/fimmu.2018.00550.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBacterial ProteinsCell DegranulationCells, CulturedCentral Nervous SystemCromolyn SodiumHumansImmunity, InnateMaleMast CellsMeningitis, PneumococcalMiceMice, Inbred C57BLMice, TransgenicMutationPneumococcal InfectionsProto-Oncogene Proteins c-kitStreptococcus pneumoniaeStreptolysinsConceptsBone marrow-derived mast cellsCentral nervous systemSystemic infection in vivoMast cellsBone-marrow-derived mast cell degranulationMast cell engraftmentMouse bone marrow-derived mast cellsBacterial infectionsMarrow-derived mast cellsCerebrospinal fluidMutant mouse strainsMast cell-deficientExperimental pneumococcal meningitisMast cell stabilizerSystemic bacterial infectionInfection in vivoDisease phenotypeCell deficiencyCSF pleocytosisPneumococcal serotypesC-kitCell engraftmentPneumococcal meningitisMouse strainsNervous systemNovel and preclinical treatment strategies in pneumococcal meningitis
Bewersdorf J, Grandgirard D, Koedel U, Leib S. Novel and preclinical treatment strategies in pneumococcal meningitis. Current Opinion In Infectious Diseases 2018, 31: 85-92. PMID: 29095719, DOI: 10.1097/qco.0000000000000416.Peer-Reviewed Original ResearchConceptsAdjuvant therapyPneumococcal meningitisNew adjuvant therapiesSystematic clinical testingProtein-based pneumococcal vaccinesPreclinical treatment strategiesPneumococcal conjugate vaccineAnti-inflammatory therapyImprove disease outcomesToxic bacterial productsMatrix metalloproteinase inhibitorsNonbacteriolytic antibioticsAdjuvant dexamethasoneLife-threatening diseaseMeningeal inflammationBacterial meningitisSerotype replacementTreatment optionsConjugate vaccinePneumococcal vaccineMorbidity rateComplement inhibitorsTreatment strategiesSuppress inflammationMeningitis